Previous close | 9.83 |
Open | 9.80 |
Bid | 9.83 x 0 |
Ask | 9.85 x 0 |
Day's range | 9.71 - 9.86 |
52-week range | 7.16 - 10.08 |
Volume | |
Avg. volume | 180,993 |
Market cap | 2.102B |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.18 (1.87%) |
Ex-dividend date | 17 May 2024 |
1y target est | N/A |
Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).